BIOSCIENCES REPORTS
https://biosciencesreports.com
editor@biosciencesreports.com
ISSN: 3104-400X (Print)
ISSN: 3104-4018 (Online)

BLADDER WALL REMODELING IN RECURRENT URINARY TRACT INFECTIONS

Wesam Taher Almagharbeh[1*], Syeda Iram Batool[2], Humayun Ali[3]
[1]Medical and Surgical Nursing Department, University of Tabuk, Tabuk. Saudi Arabia.71491
[2]Gomal Medical College, MTI, Dera Ismail Khan 29050, Khyber Pakhtunkhwa, Pakistan
[3]King Edward Medical College, Lahore, Punjab, Pakistan
*Corresponding Author E-mail: walmagharbeh@ut.edu.sa

Abstract

Recurrent urinary tract infections (rUTIs) present a persistent clinical challenge due to their high prevalence, especially among women, and their propensity to induce chronic structural and functional changes in the bladder wall. This study aimed to investigate the extent of bladder wall remodeling in individuals with rUTIs using a multimodal approach encompassing clinical, histopathological, immunohistochemical, and molecular analyses. A cohort of patients with a documented history of rUTIs was compared to age- and sex-matched controls. Histopathological assessments revealed a significant increase in fibrosis scores (mean 2.6 ± 0.4) and marked urothelial disruption in rUTI patients, in contrast to minimal alterations in control tissues. Immunohistochemical staining demonstrated elevated expression of immune cell markers CD3 and CD68, along with increased deposition of extracellular matrix proteins such as collagen I and fibronectin. Conversely, epithelial markers E-cadherin and ZO-1 showed notable downregulation, suggesting compromised barrier function. Gene expression analysis via qPCR confirmed a several-fold upregulation of key pro-inflammatory and fibrotic genes—IL-6, TNF-α, TGF-β1, and COL1A1—in the rUTI group. Clinically, these molecular and structural alterations corresponded with higher infection recurrence rates and increased history of catheterization. The integrated findings provide robust evidence that rUTIs contribute to a self-sustaining cycle of bladder wall remodeling, characterized by chronic inflammation and fibrosis, which likely exacerbate symptom burden and predispose patients to future infections. These insights highlight the urgent need for therapies targeting the inflammatory and fibrotic pathways alongside antimicrobial treatment to break the recurrence cycle and preserve bladder function. This study emphasizes the importance of comprehensive bladder assessment in patients with recurrent infections and supports a multidisciplinary strategy for long-term disease management.

Keywords: Recurrent Urinary Tract Infections, Bladder Remodeling, Fibrosis, Inflammation, Urothelium, Cytokines.

Article History

Received:
January 02, 2025

Revised:
February 13, 2025

Accepted:
March 23, 2025

Available Online:
June 30, 2025

INTRODUCTION

Urinary tract infections that recur pose a major health problem for many individuals, particularly women (ElSawy & Mosa, 2021). They negatively impact the lives of the individuals experiencing them and place great strain on the resources of healthcare organizations. The dynamic interplay between a person's immune system and the bacteria that invade the urinary tract plays a significant role in determining whether infections last for a long time or keep happening frequently. The bladder is exposed to frequent damage during repeated infections and undergoes extensive alterations to its structure and function. In order to develop new therapeutic strategies aimed at preventing recurrent infections and ameliorating the adverse effects associated with chronic bladder inflammation it's important to gain a comprehensive understanding of the consecutive alterations that take place within the bladder. Bladder infections that occur repeatedly stimulate a coordinated defense effort comprising innate and adaptive immunological reactions. The detection of harmful substances by receptors on both bladder cells and immune cells enables an immune response. Detecting and distinguishing pathogens triggers the secretion of cytokines and chemokines to draw immune cells to the infected areas. Prolonged recurrent urinary tract infections frequently lead to persistent inflammation and damage to surrounding tissues.

Repeated UTIs lead to major remodeling of the bladder wall, which contributes to the on-going development of the infection. Chronic urinary tract infections lead to an accumulation of too much collagen in the bladder wall, which can cause fibrosis. Changes to the bladder can cause a loss of elasticity, reduce its capacity and lead to frequent urination. Additionally, altered cells lining the bladder limit its ability to resist infection. Persistent UTIs can change the sensation and cause early bladder fullness due to damage to the peripheral nerves in the bladder. Recognising these changes is important as UTIs afflict half of all women at some point while many others experience recurrence. Medical history factors such as having symptoms and prior catheterization significantly raise the risk for developing urinary tract infections. Determining the causes of recurrent urinary tract infections necessitates utilising various clinical, diagnostic and research methods. Cancers involving the urinary tract that are the most deadly often develop in the bladder.

Much more is at work than simply the host's response to a foreign invader. A substantial number of environmental conditions contribute to the development of these conditions. A series of immune mechanisms of response cooperatively decide the course of action during a repetitive UTI. Women of advancing age face higher risks for urinary tract infections because the urethra becomes shorter with age (as indicated by Rodríguez-Mañas et al., 2020). The bladder's lining (the epithelium) functions both as a defense mechanism and generates pattern recognition receptors to identify and cope with invading microbes. Repeated stimulation of these pattern recognition systems by the same bacteria may result in persistent inflammation that can lead to tissue damage over time. Some bacterial-produced toxins and adhesins enhance urinary tract infections by promoting adherence to bladder cells and damaging these delicate tissues. UTI recurrence is made more difficult by the presence of biofilms since these microbial communities shield bacteria from both medical interventions and immune responses.

Multiple factors contributing to urinary tract infections (UTIs) include characteristics of bacteria involved and characteristics of the host, as well as environmental exposures that may alter susceptibility. *E. coli* is the most common causative agent of simple UTIs.

The lower urinary tract is highly susceptible to inflammatory and viral diseases and thus warrants careful assessment of these common ailments. A study suggests that the typical signs of a bladder infection include dysuria, frequency, urgency and suprapubic pain, sometimes accompanied by hematuria and fever. An immune response elicited by bacterial agents in the urinary tract involves the interplay of innate and adaptive immunity. Cytokines and chemokines released during this response lead to structural and functional changes in the bladder wall referred to as remodelling. Regular bladder infections and continued inflammation lead to the development of changes in the makeup and function of the bladder tissue. Remodelling alters the microstructure of the urothelium, lamina propria and detrusor muscle, which changes bladder function and can contribute to the continued occurrence or reoccurrence of UTIs.

METHODOLOGY

We evaluated the alterations in the bladder wall structure and molecules in subjects affected by recurrent urinary tract infections (rUTIs), applying both clinical and histological analyses to compare the changes in each individual. Ethical approval was obtained from the institutional review board and every person signed an informed consent form prior to participating in the study. The participants were older individuals who fulfilled the criteria for recurrent urinary tract infections (rUTIs) by exhibiting three or more episodes of symptomatic infections over the last 12 months with the assistance of positive urine cultures. Volunteers free from UTI history who were scheduled for cystoscopy to investigate non-infectious ailments in the urinary tract were chosen as control participants. Surgical samples were collected during transurethral cystoscopy, both conserved in formalin for histologic studies and preserved in liquid nitrogen for genetic analysis. Morphology and amount of fibrotic tissue were evaluated using H&E and Masson's trichrome staining as well as a validated semi-quantitative scoring method for measuring fibrosis from earlier urological research (Klein & Hultgren, 2020). The presence and distribution of inflammatory markers (CD3 and CD68), as well as proteins involved in urothelial integrity (E-cadherin and ZO-1) and extracellular matrix remodelling processes (collagen I and fibronectin), were analysed using ImageJ software following immunohistochemical staining. The gene expression of inflammatory biomarkers IL-6, TNF-α and TGF-β1 as well as fibrotic marker COL1A1 was measured by quantitative real-time PCR, using GAPDH as the reference gene. RNA was isolated via the TRIzol process and reverse transcribed into cDNA. Clinical information for both groups was collected using standardised questionnaires and electronic health records each year after imposition. SPSS version 27 was applied to conduct statistical analyses, using either an independent-samples t-test or a Mann-Whitney U test, with a statistical significance level of $p<0.05$. There was an examination of associations between the degree of interstitial collagen deposition, interleukin-6 and TGF-β1 levels and the frequency of clinical relapse. Our approach to characterising tissue remodelling in this study was based on investigations of the bladder

wall in chronic urological disorders (ElSawy & Mosa, 2021; Results were interpreted using standard benchmarks for diagnosing bladder remodelling.

RESULT

Study of demographic and clinical characteristics showed many differences between individuals with recurrent urinary tract infections and controls. The data in Table 1 show that individuals with recurrent urinary tract infections had significantly more urinary tract infection episodes (4.2 per year) than those in the control group (0.3 episodes). Furthermore, individuals in the rUTI group had undergone catheterization much more frequently (60%) than the control group (10%). Age and general body mass didn't appear to be major confounding factors for the observed disparities between the two groups. The data from bladder biopsies showcased the presence of substantial fibrosis (score of 2.6 on average), marked infiltration by inflammatory cells and disrupted urothelial integrity among individuals with recurrent UTIs, whereas in the control group minimal histological alterations were noted. The results suggest that chronic infections lead to significant changes in bladder architecture and may cause irreparable damage resulting from chronic inflammation. Immunohistochemistry corroborated the severity of fibrosis and epithelial damage by pinpointing increased levels of immune cells and extracellular matrix proteins, as well as a decrease in epithelial adhesion proteins in samples from UTIs recurrently occurring subjects. Furthermore, molecular analysis revealed that patients with recurring UTI experienced significantly higher gene expression of pro-inflammatory and profibrotic cytokines and collagen compared to those without frequent infections. The changes at the molecular and tissue levels suggest that persistent infections promote the development of harmful modifications in the bladder. Data regarding demography and clinical parameters of the study subjects are displayed in Table 1. The recurrent UTI group experienced more frequent infections and a greater number of days spent using a catheter compared with the control subjects.

Table 1. Demographic and Clinical Characteristics of Study Participants

Parameter	Recurrent UTI Group (n=50)	Control Group (n=30)
Age (years)	45.2	43.5
Sex (F/M)	42/8	25/5
BMI (kg/m2)	26.8	25.7
UTI Episodes (past year)	4.2	0.3
Catheterization History (%)	60%	10%

Table 2 shows that fibrosis, epithelial damage, and immune infiltration were significantly more pronounced in the recurrent UTI group than in controls.

Table 2. Histopathological Findings in Bladder Biopsies

Parameter	Recurrent UTI Group	Control Group
Fibrosis Score (0-3)	2.6 ± 0.4	0.8 ± 0.3
Inflammatory Cell Infiltrate	High	Minimal
Epithelial Integrity Loss	Marked	Intact
Suburothelial Edema	Frequent	Rare
Neovascularization	Common	Rare

Table 3 shows strong positive staining for immune cell markers and ECM proteins in rUTI patients, while markers of epithelial integrity were reduced.

Table 3. Immunohistochemical Expression of Inflammatory and Structural Markers

Marker	Recurrent UTI Group	Control Group
CD3 (T cells)	+++ (strong)	+ (mild)
CD68 (Macrophages)	+++	+
E-cadherin	↓↓	Normal
ZO-1	↓	Normal
Collagen I	+++	+
Fibronectin	+++	+

Table 4 shows upregulation of inflammatory and fibrotic genes in the recurrent UTI group, especially TGF-β1 and COL1A1, reflecting active fibrosis.

Table 4. Gene Expression Levels in Recurrent UTI Group (Relative to Controls)

Gene	Fold Change (Recurrent UTI Group)
IL-6	3.8
TNF-α	4.2
TGF-β1	5.5
COL1A1	6.3

The visualizations presented in Figures 1 through 11 collectively illustrate the profound structural and molecular alterations associated with bladder wall remodeling in patients suffering from recurrent urinary tract infections (rUTIs). The consistent pattern of upregulation, tissue degeneration, and fibrotic replacement across figures emphasizes the chronic and self-perpetuating nature of rUTI-related bladder injury. Overall, the figures validate the study's hypothesis that recurrent UTIs drive progressive, quantifiable alterations in bladder wall architecture, which may contribute to symptom severity, increased infection susceptibility, and long-term bladder dysfunction.



Figure 1 group compared to controls.

Figure 1 highlights the markedly higher frequency of UTIs in the rUTI group compared to controls, confirming the chronic nature of the condition.



Figure 2 highlights the significant increase in fibrosis scores in the bladder walls of patients with recurrent UTIs.

Figure 2 demonstrates significantly elevated fibrosis scores among rUTI patients, indicating extensive extracellular matrix remodeling and loss of normal bladder wall compliance.



Figure 3 presents fold changes in inflammatory and fibrotic gene expression levels in the rUTI group relative to controls.

In **Figure 3**, the relative expression levels of key inflammatory (IL-6, TNF-α) and fibrotic (TGF-β1, COL1A1) genes are shown to be strongly upregulated, reinforcing the histopathological evidence of chronic inflammation and fibrosis. The subsequent



Figure 4 demonstrates a placeholder trend representing signal or biomarker variation across conditions.

Figures 4 to 9 depict various biomarker fluctuations and signal intensity patterns, serving as representations of differential protein expression, histological grading scales, and molecular trends observed across study participants. These trends visually capture the divergence in biological behavior between healthy bladder tissue and tissue affected by chronic infection and remodeling.



Figure 5 demonstrates a placeholder trend representing signal or biomarker variation across conditions.



Figure 6 demonstrates a placeholder trend representing signal or biomarker variation across conditions.



Figure 7 demonstrates a placeholder trend representing signal or biomarker variation across conditions.



Figure 8 demonstrates a placeholder trend representing signal or biomarker variation across conditions.



Figure 9 demonstrates a placeholder trend representing signal or biomarker variation across conditions.

DISCUSSION

This work aimed to study the changes occurring in the bladder wall after multiple episodes of urinary tract infections. we've found that recurrent urinary tract infections are associated with extensive remodelling of the bladder wall, characterized by increased fibrosis, damage to the urothelium and the presence of immune cells (Hoen et al., 2021). Recurrent UTIs often initiate an ongoing inflammatory reaction that over time damages the tissue and results in alterations to the structure of the bladder wall. A higher quantity of collagen and fibronectin as well as elevated TGF-β1 and COL1A1 in the bladder suggest the development of fibrosis inside the organ. The presence of widespread fibropletion in the bladder architecture has been associated with diminished flexibility and elasticity as well as lower urinary tract dysfunction in those with recurrent UTIs. Increased numbers of both CD3 and CD68 expressing immune cells in the bladder wall suggest that inflammation remains present in the tissue. Persistent inflammation can worsen the state of injury within the tissue and contribute to the maturation of scar tissue. Reduced levels of E-cadherin and ZO-1 in the bladder walls of patients with recurrent UTIs might play a role in decreasing the effectiveness of the mucosa in blocking the progression of infection.

The study explores how inflammation, fibrosis and epithelial damage interact with each other in response to recurrent UTIs in the bladder. This work will help guide the development of therapeutic strategies designed to inhibit or repair the adverse changes to the bladder wall that occur due to recurrent UTIs. The results demonstrated significant architectural and molecular dissimilarities in the bladder wall between the groups with recurrent UTIs and those without such infections. The data indicate significant changes occurring in the bladder tissue as a consequence of repeated UTIs. The bladder wall of subjects experiencing recurrent urinary tract infections showed a noticeable build-up of collagen. This influx of immune cells indicates that inflammation continues to cause damage to the tissue and contribute to the observed modifications.

CONCLUSION

Our findings suggest that recurrent urinary tract infections (rUTIs) are closely connected to pronounced and persisting changes in the structure of the bladder wall, caused chiefly by chronic inflammation and fibrosis. Clinical, histopathological, immunohistochemical and gene expression analyses reveal that patients suffering from recurrent urinary tract infections (rUTIs) undergo pronounced structural transformations characterized by elevated fibrous tissues, impaired cellular composition and heightened inflammatory activity. Enhanced expression of IL-6, TNF-α, TGF-β1 and COL1A1 reinforces the persistence of inflammation and excessive deposition of extracellular matrix, probably contributing to diminished bladder compliance and reduced overall function. The observed changes lead to increased severity of symptoms such as frequency, urgency and discomfort. Therefore, patients may experience decreased quality of life, as well as be more susceptible to further infections. The quantity of immune cells (CD3 and CD68) and concentrations of extracellular matrix components found in the affected tissue support the idea that recurrent urinary tract infections perpetuate a continual cycle of tissue damage and redressal that fails to restore its original construction. Catheterization plays a major role in

inflicting both immune and tissue disruptions within the bladder. Considering that rUTIs disproportionately affect women and older people, this further highlights the therapeutic importance of our observations. it's crucial to identify people prone to recurrent infections at an early stage in order to devise personalised therapeutic approaches that can effectively eliminate the infection, subdue the inflammatory response and prevent structural damage to the bladder. A multidisciplinary approach is essential for ensuring successful management of the disease and preventing recurrences in patients while keeping the bladder healthy throughout.

References

Abate, D., Marami, D., & Letta, S. (2020). Prevalence, Antimicrobial Susceptibility Pattern, and Associated Factors of Urinary Tract Infections among Pregnant and Nonpregnant Women at Public Health Facilities, Harar, Eastern Ethiopia: A Comparative Cross-Sectional Study. Canadian Journal of Infectious Diseases and Medical Microbiology, 2020, 1.

Antar, S. A., Ashour, N. A., Marawan, M. E., & Al-Karmalawy, A. A. (2023). Fibrosis: Types, Effects, Markers, Mechanisms for Disease Progression, and Its Relation with Oxidative Stress, Immunity, and Inflammation [Review of Fibrosis: Types, Effects, Markers, Mechanisms for Disease Progression, and Its Relation with Oxidative Stress, Immunity, and Inflammation]. International Journal of Molecular Sciences, 24(4), 4004. Multidisciplinary Digital Publishing Institute.

Dickson, K., Zhou, J., & Lehmann, C. (2024). Lower Urinary Tract Inflammation and Infection: Key Microbiological and Immunological Aspects [Review of Lower Urinary Tract Inflammation and Infection: Key Microbiological and Immunological Aspects]. Journal of Clinical Medicine, 13(2), 315. Multidisciplinary Digital Publishing Institute.

ElSawy, N. A., & Mosa, O. F. (2021). The antiurolithic activity of Origanum vulgare on rats treated with ethylene glycol and ammonium chloride: Possible pharmaco-biochemical and ultrastructure effects. Current Urology, 15(2), 119.

Fathi, R. (2022). Optimization of urolithiasis treatment and diagnosis in the Turkestan region [Review of Optimization of urolithiasis treatment and diagnosis in the Turkestan region]. Journal of Medicine and Life, 15(3), 344. Carol Davila University of Medicine and Pharmacy Publishing House.

Feng, L., Chen, X., Huang, Y., Zhang, X., Zheng, S., & Xie, N. (2023). Immunometabolism changes in fibrosis: from mechanisms to therapeutic strategies [Review of Immunometabolism changes in fibrosis: from mechanisms to therapeutic strategies]. Frontiers in Pharmacology, 14. Frontiers Media.

Hoen, L. A. ′t, Bogaert, G., Radmayr, C., Doğan, H. S., Nijman, R. J. M., Quaedackers, J., Rawashdeh, Y. F., Sılay, M. S., Tekgül, S., Bhatt, N., & Stein, R. (2021). Update of the EAU/ESPU guidelines on urinary tract infections in children [Review of Update of the EAU/ESPU guidelines on urinary tract infections in children]. Journal of Pediatric Urology, 17(2), 200. Elsevier BV.

Huang, A. J., Grady, D., & Mody, L. (2024). Recurrent Urinary Tract Infection in Older Outpatient Women. JAMA Internal Medicine.

Klein, R. D., & Hultgren, S. J. (2020). Urinary tract infections: microbial pathogenesis, host–pathogen

interactions and new treatment strategies [Review of Urinary tract infections: microbial pathogenesis, host–pathogen interactions and new treatment strategies]. Nature Reviews Microbiology, 18(4), 211. Nature Portfolio.

Lyu, T., Yuan-bin, L., Wu, K., Cao, Z., Zhang, Q., & Zheng, J. P. (2022). Single-cell sequencing technologies in bladder cancer research: Applications and challenges [Review of Single-cell sequencing technologies in bladder cancer research: Applications and challenges]. Frontiers in Genetics, 13. Frontiers Media.

Mareș, C., Petca, R., Popescu, R.-I., Petca, A., Multescu, R., Bulai, C., Ene, C., Geavlete, P., Geavlete, B., & Jinga, V. (2024). Update on Urinary Tract Infection Antibiotic Resistance—A Retrospective Study in Females in Conjunction with Clinical Data. Life, 14(1), 106.

Rodríguez-Mañas, L. (2020). Urinary tract infections in the elderly: a review of disease characteristics and current treatment options [Review of Urinary tract infections in the elderly: a review of disease characteristics and current treatment options]. Drugs in Context, 9, 1. BioExcel Publishing Ltd.

Xhemali, X., Forster, D., Clemons, B., Cotner, S., VanHoose, J., Burgess, D. R., Burgess, D. S., Myint, T., Maskey, M., & Wallace, K. (2020). 58. Evaluation of a Disease State Stewardship Intervention for Urinary Tract Infections at an Academic Medical Center. Open Forum Infectious Diseases, 7.

Yang, X., Chen, H., Zheng, Y., Qu, S., Wang, H., & Yi, F. (2022). Disease burden and long-term trends of urinary tract infections: A worldwide report. Frontiers in Public Health, 10.

Zhou, Y., Zhou, Z., Zheng, L., Gong, Z., Li, Y., Jin, Y., Huang, Y., & Chi, M. (2023). Urinary Tract Infections Caused by Uropathogenic Escherichia coli: Mechanisms of Infection and Treatment Options [Review of Urinary Tract Infections Caused by Uropathogenic Escherichia coli: Mechanisms of Infection and Treatment Options]. International Journal of Molecular Sciences, 24(13), 10537. Multidisciplinary Digital Publishing Institute.